A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)


2seventy bio

Status and phase

Phase 2
Phase 1


Diffuse Large B Cell Lymphoma (DLBCL)


Biological: bbT369

Study type


Funder types




Details and patient eligibility


A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin's Lymphoma.

Full description

This is a non-randomized, open label, multi-site Phase 1/2 study. This first-in-human Phase 1/2 Study CRC-403 will evaluate the safety and efficacy of bbT369 in subjects with relapsed and/or refractory B cell non-Hodgkin's lymphoma (NHL). Phase 1 will be a dose escalation, up to a planned four dose levels. After establishing MTD, Phase 2 will enroll subjects with B cell NHL in 2 cohorts: CAR T exposed subjects (Cohort 1) and CAR T naïve subjects (Cohort 2). A long-term follow-up is planned, in which subjects who received bbT369 will be followed for up to 15 years after drug product infusion to evaluate for safety and continued efficacy.


50 estimated patients




18+ years old


No Healthy Volunteers

Inclusion criteria

  • ≥18 years of age at the time of signing informed consent.

  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

  • Diagnosis of B-cell NHL according to WHO 2017 classification or WHO 2016 classification where applicable:

    1. DLBCL (germinal center B cell [GCB] or activated B cell [ABC] type or not otherwise specified [NOS])
    2. HGBCL (with MYC and BCL2 and/or BCL6 rearrangements or NOS)
    3. PMBCL
    4. FL 3b
    5. DLBCL transformed from FL
  • Participants must have relapsed or refractory (r/r) B cell NHL after autologous stem cell transplant (ASCT) or at least 2 prior lines of therapy including an anti-CD20 monoclonal antibody and an anthracycline containing chemotherapy regimen. Note: participants with DLBCL transformed from FL must have r/r disease after ASCT or at least 2 prior therapies following transformation irrespective of therapeutic agents.

  • At least 1 FDG-avid lesion per Lugano Classification criteria at time of enrollment.

Exclusion criteria

  • Treatment with any investigational cellular therapy prior to enrollment. Treatment with an approved anti-CD19 CAR T cell therapy in an investigational setting may be permitted after discussion with and approval of the Sponsor.
  • Progression within 6 weeks of prior anti-CD19 CAR T cell therapy.
  • Residual toxicities or end-organ damage to vital organs from prior therapy that could put a subject at undue risk based on Investigator's assessment. Toxicities related to prior cytokine release syndrome (CRS) or neurotoxicity must be resolved.
  • If a subject has received prior anti-CD19 CAR T therapy, development of ≥ Grade 3 CAR T related CRS or ≥ Grade 3 neurotoxicity that in the opinion of the Investigator would cause unacceptable risk of toxicity to the subject upon treatment with bbT369.
  • Primary central nervous system (CNS) lymphoma or a history or presence of clinically relevant CNS pathology.
  • Active autoimmune disease requiring systemic immunosuppressive and/or cytotoxic therapy within the past two years.
  • Treatment with any prior anti-CD79a therapy.
  • Previous history of an allogeneic bone marrow transplantation. Autologous stem cell transplantation (ASCT) is permitted.

Trial design

Primary purpose




Interventional model

Single Group Assignment


None (Open label)

50 participants in 1 patient group

bbT369 Experimental Arm
Experimental group
Open label, single arm treatment with bbT369
Biological: bbT369

Trial contacts and locations



Central trial contact

Clinical Trials Office

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems